A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.
Financial Summary
| Share Statistics | HKMPY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,483.2 | $579.1 | 66% |
|
| Shares Out (Mil) | 222.9 | 43.0 | 78% |
|
| Institutional Ownership | 47.9% | 84.3% | 22% |
|
| Float (Mil) | 141.8 | 46.8 | 68% |
|
| Beta | 0.64 | 0.62 | 37% |
|
| Avg Daily Volume (000s) | 1 | 285 | 4% |
|
| Price Change (52-week) |
(7.9%) | 63.8% | 39% |
|
| Growth | HKMPY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.4% | 6.7% | 48% |
|
| Net Income (5yr) | (1.4%) | (1.4%) | 38% |
|
| EPS (5yr) | 0.0% | 14.9% | 31 |
|
| Dividends (5yr) | 10.9% | 0.0% | 76% |
|
| Cash Flow (5yr) | 17.7% | (14.9%) | 77% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | HKMPY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,349 | $272 | 69% |
|
| Net Income (TTM) (Mil) | $402 | ($11) | 76% |
|
| EPS (TTM) | $1.822 | ($0.500) | 70% |
|
| Operating Cash Flow (TTM) (Mil) | $436 | ($6) | 70% |
|
| Net Cash Flow (TTM) (Mil) | $29 | $4 | 66% |
|
| Long-Term Debt (Q1) (Mil) | $1,490 | $7 | 71% |
|
| Enterprise Value (Q1) (Mil) | $5,587 | $522 | 65% |
|
| Valuation | HKMPY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.73 | na |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | HKMPY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 43.5% | 65.9% | 54% |
|
| Net Margin | 12.0% | 0.7% | 68% |
|
| ROA | 7.4% | (24.6%) | 81% |
|
| ROE | 16.4% | (19.7%) | 74% |
|
| Liabilities to Assets | 54.0% | 35.5% | 46% |
|
| F-Score | na | 3 | na |
|
Hikma Pharmaceuticals PLC did not pass any screens on 7/31/2026.
